ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Overall survival update from the BREAK-3 study
ecancermedicalscience editor's choice for November 2014
Biomarker for PARP inhibitor responsiveness in ovarian cancer patients
New drug, ASP8273, shows response in Japanese patients with treatment-resistant non-small cell lung cancer
The work and aims of SPECTA for better clinical trials
New emerging treatments and challenges in MCL, MM and CLL: Expert panel discussion
Early events found to trigger lung cancer twenty years before diagnosis
Cheap DIY colorectal screening kit trialled
Potential role of blood testing for microRNA profiles in paediatric cancers
Interventional oncology: The next oncological discipline
Cancer genomics and pancreatic cancer